🔗 Permalink

Inventor profile of:

Eric Elenko

City:

Boston, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2026-02-12

Top Assignees for applications by Eric Elenko

The entities that hold a legal rights for patent applications filed by inventor Elenko Eric:

PureTech Health, LLC 9 Boston, MA United States
NEW YORK UNIVERSITY 6 New York, NY United States
PURETECH LYT, INC. 6 Boston, MA United States
Akili Interactive Labs, Inc. 4 Boston, MA United States
PureTech LYT 100, Inc. 2 Boston, MA United States
GELESIS LLC 1 Boston, MA United States
Pure Tech LYT 100, Inc. 1 Boston, MA United States
BEIGENE SWITZERLAND GMBH 1 Basel, Switzerland
PureTech Ventures 1 Boston, MA United States
Pure Tech Ventures, LLC 1 Boston, MA United States

Recent patent applications by Elenko Eric

Eric Elenko from Boston, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-02-12

US20260042846A1

Chemistry; metallurgy

ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

#2 | 2025-12-11

US20250375431A1

Human necessities

METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS WITH DEUPIRFENIDONE

#3 | 2025-10-30

US20250333506A1

Chemistry; metallurgy

ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR

#4 | 2025-08-28

US20250269019A1

Human necessities

ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF

#5 | 2025-04-10

US20250114341A1

Human necessities

METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS WITH DEUPIRFENIDONE

#6 | 2025-04-10

US20250114340A1

Human necessities

METHODS OF TREATING INTERSTITIAL LUNG DISEASES AND OTHER FIBROTIC-MEDIATED PULMONARY DISEASES AND DISORDERS WITH DEUPIRFENIDONE

#7 | 2025-01-23

US20250025450A1

Human necessities

METHODS OF TREATING INTERSTITIAL LUNG DISEASES AND OTHER FIBROTIC-MEDIATED PULMONARY DISEASES AND DISORDERS WITH DEUPIRFENIDONE

#8 | 2024-10-31

US20240358690A1

Human necessities

METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS WITH DEUPIRFENIDONE

#9 | 2024-08-29

US20240287195A1

Chemistry; metallurgy

ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF IN THE TREATMENT OF OCULAR MELANOMA

#10 | 2024-06-13

US20240190970A1

Chemistry; metallurgy

ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF

#11 | 2024-06-06

US20240182583A1

Chemistry; metallurgy

COMBINATION OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS FOR USE IN CANCER THERAPY

#12 | 2024-04-04

US20240109968A1

Chemistry; metallurgy

ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF

#13 | 2024-03-28

US20240100039A1

Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION

#14 | 2024-02-08

US20240043543A1

Chemistry; metallurgy

ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF

#15 | 2024-01-11

US20240008799A1

Human necessities

Processor Implemented Systems and Methods for Measuring Cognitive Abilities

#16 | 2023-08-17

US20230255946A1

Human necessities

METHODS OF TREATING DISEASES AND DISORDERS WITH DEUPIRFENIDONE

#17 | 2023-04-27

US20230129866A1

Human necessities

METHODS OF TREATING RESPIRATORY DISEASE WITH DEUPIRFENIDONE

#18 | 2023-02-09

US20230040415A1

Human necessities

METHODS OF TREATING LYMPHEDEMA WITH DEUPIRFENIDONE

#19 | 2022-10-27

US20220340666A1

Chemistry; metallurgy

Anti-galectin-9 antibodies and uses thereof

#20 | 2022-10-20

US20220332832A1

Chemistry; metallurgy

COMBINED CANCER THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS

#21 | 2022-10-20

US20220332830A1

Chemistry; metallurgy

ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

#22 | 2022-06-30

US20220204629A1

Chemistry; metallurgy

ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

#23 | 2022-06-16

US20220185896A1

Chemistry; metallurgy

ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

#24 | 2022-06-09

US20220178930A1

Physics

ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

#25 | 2022-04-21

US20220117528A1

Human necessities

Processor implemented systems and methods for measuring cognitive abilities

#26 | 2022-03-10

US20220073612A1

Chemistry; metallurgy

Antibodies specific to delta 1 chain of T cell receptor

#27 | 2021-07-08

US20210205283A1

Human necessities

DEUTERIUM-ENRICHED PIRFENIDONE AND METHODS OF USE THEREOF

#28 | 2020-10-15

US20200323839A1

Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION

#29 | 2020-03-26

US20200093810A1

Human necessities

DEUTERIUM-ENRICHED PIRFENIDONE AND METHODS OF USE THEREOF

#30 | 2020-01-09

US20200010551A1

Chemistry; metallurgy

Anti-galectin-9 antibodies and uses thereof

#31 | 2019-11-21

US20190351061A1

Human necessities

USE OF POLYMERIC MATERIALS WITH OTHER SUBSTANCES FOR IMPROVED PERFORMANCE

#32 | 2019-10-10

US20190307739A1

Human necessities

Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

#33 | 2019-08-22

US20190256604A1

Chemistry; metallurgy

Anti-galectin-9 antibodies and uses thereof

#34 | 2019-06-27

US20190192500A1

Human necessities

Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

#35 | 2019-06-06

US20190167658A1

Human necessities

Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

#36 | 2019-05-02

US20190127472A1

Chemistry; metallurgy

Anti-Galectin-9 antibodies and uses thereof

#37 | 2017-04-27

US20170112820A1

Human necessities

Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

#38 | 2017-04-06

US20170098385A1

Physics

Processor-implemented systems and methods for enhancing cognitive abilities by personalizing cognitive training regimens

#39 | 2017-04-06

US20170095465A1

Human necessities

Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

#40 | 2016-09-15

US20160262680A1

Human necessities

Processor implemented systems and methods for measuring cognitive abilities

#41 | 2015-09-24

US20150265593A1

Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION

#42 | 2015-07-16

US20150196641A1

Human necessities

Use of polymeric materials with other substances for improved performance

#43 | 2014-04-10

US20140099356A1

Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION

#44 | 2011-01-27

US20110020423A1

Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION

#45 | 2009-12-17

US20090311235A1

Human necessities

Use of Polymeric Materials with Other Substances for Improved Performance

InventorID:

718962 ⎘